| 摘要 |
The present invention relates to anti-CD277 antibodies which: -activates or inhibit cytolytic function of V?9/ Vd2 T cells, and/or -costimulates T cells together with CD3-TCR, and/or -costimulates T cells in addition to CD28-B7 costimulation, and/or -increases the activity and/or survival of monocytes and dendritic cells. the invention also relates to the use of said antibodies in therapy. |
